Efficacy and safety of oxaliplatin or irinotecan combined with capecitabine in the treatment of metastasis colorectal carcinoma
10.13699/j.cnki.1001-6821.2014.10.011
- VernacularTitle:卡培他滨联合奥沙利铂或伊立替康治疗转移性结直肠癌的疗效与安全性
- Author:
Chong-Yuan LIU
1
;
Lu-Min LV
;
Bao-Kang XU
Author Information
1. 武夷山市立医院 普通外科
- Keywords:
metastasis colorectal carcinoma;
capecitabine;
oxaliplatin;
irinotecan
- From:
The Chinese Journal of Clinical Pharmacology
2014;(10):907-908,918
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of oxaliplatin (L -OHP) or irinotecan ( CPT -11 ) combined with capecitabine (CAP) in the treatment of metastasis colorectal carcinoma.Methods Sixty -six patients with metastasis colorectal carcinoma were recruited in this study.There were 31 cases in CAP plus L -OHP group and 35 sub-jects in CAP plus CPT -11 group.All of the included cases were treated with 4 cycles of chemotherapy.The clinical efficacy and chemotherapy related side effects were compared between the two groups .Results The objective response rate (ORR) were 19.4% and 20.0% in the CAP plus L -OHP and CAP plus CPT -11 group respectively without statistical difference (P >0.05).The grade Ⅲ to Ⅳ adverse reactions in the CAP plus CPT -11 group and CAP plus L -OHP group were 51.6% and 60.0%, without statistical differences in two groups (P >0.05) .But diarrhea incidence in the CAP plus CPT -11 group (22.9%) was much higher than that in the CAP plus L -OHP group (3.2%) (P <0.05). Conclusion There was no statistical difference on clinical efficacy between the two chemotherapy regimens, but there is a higher incidence of serious diarrhea in CAP plus CPT -11 regimen.
